Fig. 6

GV-971 significantly reduces glial inflammation in 9 month old 5XFAD male mice. a Representative images of brains stained for GFAP⁺ astrocytes in 5XFAD mice from Washington University in St. Louis. b, c Quantification of %area covered by GFAP⁺ astrocytes in whole brain, cortices and hippocampus of 5XFAD mice treated with 100 mg/kg GV-971 or vehicle (male = 13, female = 9–12). d Representative images of brains stained for Iba-1⁺ microglia. e, f Quantification of % area covered by Iba-1⁺ microglia in whole brain, cortices and hippocampus of 5XFAD mice treated with 100 mg/kg GV-971 or vehicle (male = 13, female = 9–12). g Representative images of Iba-1⁺ microglia (green) clustering around Aβ plaque (blue). h, i Quantification of the average number of Iba-1⁺ surface within 3 μM radius of Aβ plaque in cortices of 5XFAD mice treated with 100 mg/kg GV-971 or vehicle (male = 13, female = 9–12). j Representative images of Clec7a⁺ microglia (red) clustering around Aβ plaque (blue). k, l Quantification of the average number of Clec7a⁺ surface within 15 μM radius of Aβ plaque in cortices of 5XFAD mice treated with 100 mg/kg GV-971 or vehicle (male = 13, female = 9–12). m Representative images of P2ry12⁺ microglia (red) clustering around Aβ plaque (blue). n, o Quantification of the average number of P2ry12⁺ surface within 15 μM radius of Aβ plaque in cortices of 5XFAD mice treated with 100 mg/kg GV-971 or vehicle (male = 13, female = 9–12). Data presented as SEM. Significance determined using unpaired t-test (d). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001